cases with ischemic cerebrovascular diseases caused by
blood rheology disorders were treated with
lumbrokinase capsules,among
them 192 cases were involved in the randomized,double blind, placebo controlled clinical trial of
lumbrokinase or placebo group and 112cases were involved in the open clinical trial of lumbroinase group.The results of the randomized, double blind, placebo controlled clinicaltrial revealed that the lumbrokinase capsules (400 mg) could reduce thehemagglutination index, plasma fibrinogen(g/L) whole blood viscosity(mPa·s,230 l/s), plasma viscosity(mPa·s) and could improve the rheology scores and the symptom scores,the difference between the lumbrokinase and placebo groups was significant(P<0.05-0.001); the results of the open clinical trial showed that the lumbrokinase capsules could reduce the dry weight of the thrombosis in vitro, platelet aggregation rate,whole blood viscosity(230,46,5.75 l/S) and could improve the
blood rheology scores and symptom scores, the difference between before and after treatment was significant(P<0.05-0.001). The overall effective rates of double blind lumbrokinase group for subjective symptoms and blood rheology disorders of the CVD patients were 84.5% and 91.5% respectively, and of placebo group were 22.2% and 41.3% respectively(P<0.001). Only a few patients had adverse drug reactions and did not take special treatment. It suggests that lumbrokinase is an effective and safe drug for prevention and treatment of ischemic cerebrovascular diseases with blood rheology disorders.